Genetics, Pathophysiology, and Treatment of Recessive Autoinflammatory Diseases
Genetics, Pathophysiology, and Treatment of Recessive Autoinflammatory Diseases
批准号:
10499931
负责人:
Daniel Kastner
金额:
$222.17万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
ARID1A geneAgeAnimal ModelAnimalsArthritisAutoimmuneBiochemicalBiologyCell DeathCell LineCellsChromatinChronicCleaved cellClinicalClinical ResearchCollaborationsDefectDevelopmentDiagnosisDiseaseEmbryoEmbryonic DevelopmentEnhancersExhibitsFibroblastsFunctional disorderGene ExpressionGene FrequencyGenesGeneticGenomicsGoalsHTATIP2 geneHematologyHepatitis B VirusHumanIn VitroIndividualInflammatoryInheritedInterferonsInterleukin-6JournalsLeadLinkManuscriptsMedicineMicroscopic polyangiitisMinorMutationNF-kappa BNamesNational Institute of Dental and Craniofacial ResearchNew EnglandPaperPathogenicityPatientsPhenotypePolyarteritis NodosaProteinsPublishingRIPK1 geneRegulationReportingRheumatologyRoleSamplingScienceSerumSignal TransductionStroke preventionSyndromeSystemTBK1 geneTNF geneTestingUbiquitinVariantVasculitisVirus DiseasesWegener&aposs Granulomatosisadenosine deaminase deficiencyautoinflammationautoinflammatorychromatin remodelingcohortcongenital anomalyconsanguineous familyenzyme activityexperiencehistone deacetylase 2improvedin vivoinhibitor/antagonistknockin animalknockout animalloss of function mutationperipheral bloodpreventprotein functionresponse
中文摘要
在本报告所述期间,我们重点开展了以下项目:
英文摘要
During the current reporting period we focused on the following projects:
1) Deficiency of adenosine deaminase 2 (DADA2)
In a previous reporting period, we published a manuscript in the New England Journal of Medicine demonstrating the efficacy of tumor necrosis factor (TNF) inhibitors in preventing strokes in DADA2. Our current cohort of DADA2 patients is now more than 55 patients, and we continue to observe that TNF inhibitors are highly effective in preventing strokes, although TNF inhibition does not appear to be effective in preventing the hematologic manifestations of DADA2.
In collaboration with Peter Merkel and the Vasculitis Clinical Research Consortium, we have screened 117 patients with idiopathic polyarteritis nodosa (PAN), all of whom tested negative for hepatitis B virus infection, for ADA2 mutations. Four (3.4%) had biallelic rare missense variants in ADA2 with a minor allele frequency of less than 0.005. Of the 7 distinct variants present in these 4 patients, 6 had previously been reported as causative for DADA2, and the remaining variant is computationally predicted to be damaging to protein function. Four additional patients were carriers for monoallelic variants, one of which has been reported in DADA2 before. Serum samples from 2 patients with PAN with biallelic variants were available and showed markedly reduced ADA2 enzyme activity. ADA2 enzyme activity testing of 86 additional patients revealed 1 individual with strongly reduced ADA2 activity without detectable pathogenic variants. Patients with PAN and biallelic variants in ADA2 were younger at diagnosis than patients with 1 or no variant at ADA2, with no other clinical differences noted. Of 1107 patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), none were homozygous or compound heterozygous for ADA2 mutations. A manuscript describing these findings was published in Arthritis and Rheumatology in March.
2) Description of LINKED, an X-linked recessive disorder presenting with multiple congenital anomalies and hemizygous mutations in OTUD5
Relying on genomic constraint scores, we identified 10 patients with multiple congenital anomalies caused by hemizygous variants in OTUD5, encoding a K48/K63 linkage-specific deubiquitylase. In collaboration with Achim Werner in NIDCR, we found that OTUD5 controls neuroectodermal differentiation through cleaving K48-linked ubiquitin chains to counteract degradation of select chromatin regulators (e.g., ARID1A/B, histone deacetylase 2, and HCF1), mutations of which underlie diseases that exhibit phenotypic overlap with OTUD5 patients. Loss of OTUD5 during differentiation leads to less accessible chromatin at neuroectodermal enhancers and aberrant gene expression. This study defined a previously unidentified disorder we named LINKED (LINKage-specific deubiquitylation deficiency-induced Embryonic Defects) syndrome that reveals linkage-specific ubiquitin cleavage from chromatin remodelers as an essential signaling mode that coordinates chromatin remodeling during embryogenesis. A paper describing these findings was published in Science Advances in January.
3) Autoinflammation due to TBK1 deficiency
A collaborative study with Dusan Bogunovic identified four patients, ages 32, 26, 7, and 8 from 3 unrelated consanguineous families with homozygous loss-of-function mutations in TBK1, a regulator of IFN-I, NF-kB, and TNF-induced RIPK1-dependent cell death (RCD). All 4 patients suffer from chronic and systemic autoinflammation, but not severe viral infections. We found that TBK1 loss results in hypomorphic but sufficient IFN-I induction via RIG-I/MDA5, while the system retains near intact IL-6 induction through NF-kB. Autoinflammation is driven by TNF-induced RCD as patient-derived fibroblasts experienced higher rates of necroptosis in vitro, and CC3 was elevated in peripheral blood ex vivo. Treatment with anti-TNF dampened the baseline circulating inflammatory profile and ameliorated the clinical condition in vivo. These findings highlight the plasticity of the IFN-I response and underscore a cardinal role for TBK1 in the regulation of RCD.
A manuscript describing these findings was published in Cell in August.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genetics, Pathophysiology, and Treatment of Recessive Autoinflammatory Diseases
-
批准号:8565567
-
项目类别:
-
资助金额:$112.3万
-
财政年份:--
-
负责人:Daniel Kastner
-
依托单位:
NHGRI/DIR Animal Research Infrastructure
-
批准号:8565610
-
项目类别:
-
资助金额:$29.4万
-
财政年份:--
-
负责人:Daniel Kastner
-
依托单位:
Genetics, Pathophysiology, and Treatment of Dominant Autoinflammatory Diseases
-
批准号:8750705
-
项目类别:
-
资助金额:$96.59万
-
财政年份:--
-
负责人:Daniel Kastner
-
依托单位:
Genetics, Pathophysiology, and Treatment of Recessive Autoinflammatory Diseases
-
批准号:9152742
-
项目类别:
-
资助金额:$110.74万
-
财政年份:--
-
负责人:Daniel Kastner
-
依托单位:
Genetic Analysis of Complex Inflammatory Disorders
-
批准号:10706155
-
项目类别:
-
资助金额:$234.17万
-
财政年份:--
-
负责人:Daniel Kastner
-
依托单位:
Genetic Analysis of Complex Inflammatory Disorders
-
批准号:8350022
-
项目类别:
-
资助金额:$46.04万
-
财政年份:--
-
负责人:Daniel Kastner
-
依托单位:
Clinical Support Services for the NIAMS Intramural Research Program
-
批准号:7732845
-
项目类别:
-
资助金额:$338.95万
-
财政年份:--
-
负责人:Daniel Kastner
-
依托单位:
Clinical Support Services for the NIAMS Intramural Research Program
-
批准号:7970186
-
项目类别:
-
资助金额:$461.36万
-
财政年份:--
-
负责人:Daniel Kastner
-
依托单位:
Genetics, Pathophysiology, and Treatment of Recessive Autoinflammatory Diseases
-
批准号:8948387
-
项目类别:
-
资助金额:$101.82万
-
财政年份:--
-
负责人:Daniel Kastner
-
依托单位:
Genetics, Pathophysiology, and Treatment of Dominant Autoinflammatory Diseases
-
批准号:10027215
-
项目类别:
-
资助金额:$179.37万
-
财政年份:--
-
负责人:Daniel Kastner
-
依托单位:
Genetics, Pathophysiology, and Treatment of Dominant Autoinflammatory Diseases
-
批准号:10499932
-
项目类别:
-
资助金额:$228.91万
-
财政年份:--
-
负责人:Daniel Kastner
-
依托单位:
Genetics, Natural History, and Pathophysiology of Behcet's Disease
-
批准号:8565569
-
项目类别:
-
资助金额:$112.3万
-
财政年份:--
-
负责人:Daniel Kastner
-
依托单位:
Genetic Analysis of Complex Inflammatory Disorders
-
批准号:8750703
-
项目类别:
-
资助金额:$38.64万
-
财政年份:--
-
负责人:Daniel Kastner
-
依托单位:
Genetics, Natural History, and Pathophysiology of Behcet's Disease
-
批准号:8750706
-
项目类别:
-
资助金额:$96.59万
-
财政年份:--
-
负责人:Daniel Kastner
-
依托单位:
Genetics, Pathophysiology, and Treatment of Recessive Autoinflammatory Diseases
-
批准号:10027214
-
项目类别:
-
资助金额:$179.37万
-
财政年份:--
-
负责人:Daniel Kastner
-
依托单位:
NHGRI/DIR Animal Research Infrastructure
-
批准号:10027217
-
项目类别:
-
资助金额:$80.52万
-
财政年份:--
-
负责人:Daniel Kastner
-
依托单位:
Genetics, Pathophysiology, and Treatment of Dominant Autoinflammatory Diseases
-
批准号:10268070
-
项目类别:
-
资助金额:$153.36万
-
财政年份:--
-
负责人:Daniel Kastner
-
依托单位:
Genetics, Natural History, and Pathophysiology of Behcet's Disease
-
批准号:10268071
-
项目类别:
-
资助金额:$153.36万
-
财政年份:--
-
负责人:Daniel Kastner
-
依托单位:
Genetics, Pathophysiology, and Treatment of Recessive Autoinflammatory Diseases
-
批准号:10268069
-
项目类别:
-
资助金额:$153.36万
-
财政年份:--
-
负责人:Daniel Kastner
-
依托单位:
Genetics Of The Dominantly Inherited Periodic Fever Syndromes
-
批准号:8175276
-
项目类别:
-
资助金额:$38.8万
-
财政年份:--
-
负责人:Daniel Kastner
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: